PVP-I Nasal Sprays and SARS-CoV-2 Nasopharyngeal Titers (for COVID-19)
Status:
Completed
Trial end date:
2020-12-13
Target enrollment:
Participant gender:
Summary
The study aims to determine the safety and efficacy of povidone-iodine (PVP-I) containing
nasal sprays as compared to isotonic saline nasal sprays in COVID-19 positive patients. The
primary outcome measure is SARS-CoV-2 viral titers in the nasal cavity and nasopharynx. In
vitro studies have shown PVP-I to be highly virucidal against the viruses which cause SARS
and MERS. Additionally, clinical studies have shown PVP-I saline sprays to be well tolerated
in human subjects. PVP-I oral rinses and sprays have been trialed as methods to reduce the
incidence and symptoms of viruses which cause the "common cold."